Debt-Equity Conversion Case of Shanghai Asia Pioneer Pharmaceutical Co., Ltd.

Shanghai New Asiatic Pharmaceutical Company, Shanghai Pioneer Pharmaceutical Company and Shanghai No.4 Pharmaceutical Factory were all the pioneers and cradles of Chinese antibiotic industry, and they boasted brilliant history in the past. However, in the 1990s, they were crippled by losses and even ran up outstanding debts of hundreds of millions, which were attributable to their excessive expansion. Under the approval of the State Council, Shanghai Pioneer Pharmaceutical Company was listed in the plan of debt-equity conversion. For the purpose, Shanghai Pharmaceutical Group with relevant asset management companies star reorganization of Pioneer Pharmaceutical, meanwhile invest the equity of New Asiatic and all assets of No.4 Pharmaceutical Factory in, thus the largest antibiotics production enterprise are established. The case involves debt-equity conversion of state-owned enterprise, merger, asset reorganization, equity investment and some other important legal issues. In this case, Mr. Chambers Yang provides relevant legal services and acts as its legal advisor.

  • 本站声明:本站所载之法律论文、法律评论、案例、法律咨询等,除非另有注明,著作权人均为站长杨春宝高级律师本人。欢迎其他网站链接,但是,未经书面许可,不得擅自摘编、转载。引用及经许可转载时均应注明作者和出处"法律桥",并链接本站。本站网址:。
  •         本站所有内容(包括法律咨询、法律法规)仅供参考,不构成法律意见,本站不对资料的完整性和时效性负责。您在处理具体法律事务时,请洽询有资质的律师。本站将努力为广大网友提供更好的服务,但不对本站提供的任何免费服务作出正式的承诺。本站所载投稿文章,其言论不代表本站观点,如需使用,请与原作者联系,版权归原作者所有。